Are you taking an integrated approach to pharmaceutical abuse liability assessment?
When used as advised by a doctor, prescription drugs have the potential to do a significant amount of good. However, when taken inappropriately, their use can lead to severe adverse events, including, in the case of drugs acting on the CNS, abuse and dependence. Prescription drug abuse is a growing global challenge affecting the quality of life of millions of people worldwide. According to the National Institute on Drug Abuse, an estimated 48 million people in the U.S. over the age of 12 have used prescription drugs for non-medical reasons – equivalent to one in every five people of the population. And the problem is growing.
The implementation of measures to control the prescribing practices and availability of medicines is the first line of defense against their abuse and misuse. Effective scheduling relies on pharmaceutical developers evaluating the drug’s potential for abuse. However, how can this be done in a way that ensures medicines are available to patients as quickly and as cost effectively as possible? In this article we consider the advantages of adopting an integrated approach to drug development while navigating the regulatory requirements around abuse liability assessment.